hVIVO

hVIVO is a science-led, early-phase drug development partner serving global biopharma, pharmaceutical and biotechnology clients. Its work spans clinical trial delivery, specialist laboratories, regulatory consultancy, participant recruitment, biological sample storage and human challenge studies, supporting programmes from preclinical strategy through Phase III clinical trials. For professionals working in regulated industries, the regulatory consultancy arm, which advises drug development programmes, sits alongside clinical operations that must operate within a tightly supervised scientific and containment framework.

The company's technical capabilities are concentrated in human challenge models for respiratory and infectious diseases, including influenza, RSV, human rhinovirus and human metapneumovirus. These studies are conducted in purpose-built quarantine facilities and supported by CL3 containment laboratories carrying out bioanalytical testing, virology, immunology and biomarker analysis. Secure cryostorage for biological samples forms part of an integrated delivery model that combines trials, laboratories, recruitment and storage under one organisation.

hVIVO reports approximately 1,900 completed trials and five clinical sites across the UK and Germany, with its headquarters in London and a client base that is global. It maintains a database of about 400,000 volunteers, which supports rapid enrolment and retention for complex studies, and claims more than 100 years of combined service and experience. The company is publicly listed on the London Stock Exchange AIM market under the ticker HVO.